SNDX - Syndax Pharmaceuticals, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.
IPO Date: March 3, 2016
Sector: Healthcare
Industry: Biotech
Market Cap: $1.51B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.46 | 3.15%
Avg Daily Range (30 D): $0.46 | 2.43%
Avg Daily Range (90 D): $0.52 | 2.63%
Institutional Daily Volume
Avg Daily Volume: .67M
Avg Daily Volume (30 D): 1.26M
Avg Daily Volume (90 D): 1.42M
Trade Size
Avg Trade Size (Sh.): 84
Avg Trade Size (Sh.) (30 D): 68
Avg Trade Size (Sh.) (90 D): 69
Institutional Trades
Total Institutional Trades: 3,793
Avg Institutional Trade: $2.36M
Avg Institutional Trade (30 D): $3.6M
Avg Institutional Trade (90 D): $3.05M
Avg Institutional Trade Volume: .13M
Avg Institutional Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $3.21M
Avg Closing Trade (30 D): $6.11M
Avg Closing Trade (90 D): $5.92M
Avg Closing Volume: 176.97K
 
News
May 20, 2026 @ 11:00 AM
Syndax Announces Participation in Upcoming Investo...
Source: Na
Mar 13, 2026 @ 1:09 PM
Cancer Drug Maker With $172 Million Revenue and Mu...
Source: Jonathan Ponciano
Jan 7, 2026 @ 12:00 PM
Syndax and World Orphan Drug Alliance to Launch a ...
Source: Na
Dec 1, 2025 @ 12:00 PM
Syndax Announces Participation at the 8th Annual E...
Source: Michael A. Metzger
Oct 24, 2025 @ 5:58 PM
Syndax Announces FDA Approval of RevuforjÃโ€šÂ® (rev...
Source: Syndax Pharmaceuticals
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-2.52 $-.55 $-.49
Diluted EPS $-2.52 $-.55 $-.49
Revenue $252.25M $72.79M $64.86M
Gross Profit
Net Income / Loss $-220.77M $-49.36M $-42.67M
Operating Income / Loss $-194.17M $-40M $-34.2M
Cost of Revenue
Net Cash Flow $227.73M
PE Ratio